6-Hydroxydopamine and lipopolysaccharides induced DNA damage in astrocytes: involvement of nitric oxide and mitochondria

Mutat Res Genet Toxicol Environ Mutagen. 2015 Jan 15:778:22-36. doi: 10.1016/j.mrgentox.2014.12.007. Epub 2015 Jan 6.

Abstract

The present study was conducted to investigate the effect of the neurotoxins 6-hydroxydopamine and lipopolysaccharide on astrocytes. Rat astrocyte C6 cells were treated with different concentration of 6-hydroxydopamine (6-OHDA)/lipopolysaccharides (LPS) for 24 h. Both neurotoxins significantly decreased the viability of astrocytes, augmented the expression of inducible nitric oxide synthase (iNOS) and the astrocyte marker--glial fibrillar acidic protein. A significantly decreased mitochondrial dehydrogenase activity, mitochondrial membrane potential, augmented reactive oxygen species (ROS) level, caspase-3 mRNA level, chromatin condensation and DNA damage was observed in 6-OHDA/LPS treated astroglial cells. 6-OHDA/LPS treatment also caused the significantly increased expression of iNOS and nitrite level. Findings showed that 6-OHDA/LPS treatment caused mitochondrial dysfunction mediated death of astrocytes, which significantly involve the nitric oxide. Since we have observed significantly increased level of iNOS along with mitochondrial impairment and apoptotic cell death in astrocytes, therefore to validate the role of iNOS, the cells were co-treated with iNOS inhibitor aminoguanidine (AG, 100 μM). Co-treatment of AG significantly attenuated the 6-OHDA/LPS induced cell death, mitochondrial activity, augmented ROS level, chromatin condensation and DNA damage. GFAP and caspase-3 expression were also inhibited with co-treatment of AG, although the extent of inhibition was different in both experimental sets. In conclusion, the findings showed that iNOS mediated increased level of nitric oxide acts as a key regulatory molecule in 6-OHDA/LPS induced mitochondrial dysfunction, DNA damage and apoptotic death of astrocytes.

Keywords: 6-OHDA; Aminoguanidine; Caspase-3; DNA damage; LPS; iNOS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Astrocytes / cytology
  • Astrocytes / drug effects*
  • Astrocytes / metabolism
  • Caspase 3 / genetics
  • Caspase 3 / metabolism
  • Cell Line
  • Chromatin / chemistry
  • Chromatin / drug effects
  • DNA Damage
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation
  • Glial Fibrillary Acidic Protein / genetics
  • Glial Fibrillary Acidic Protein / metabolism
  • Guanidines / pharmacology
  • Lipopolysaccharides / antagonists & inhibitors
  • Lipopolysaccharides / toxicity*
  • Membrane Potential, Mitochondrial / drug effects
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Mitochondria / pathology
  • Neurotoxins / antagonists & inhibitors
  • Neurotoxins / toxicity*
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism*
  • Oxidopamine / antagonists & inhibitors
  • Oxidopamine / toxicity*
  • Rats
  • Reactive Oxygen Species / metabolism

Substances

  • Chromatin
  • Enzyme Inhibitors
  • Glial Fibrillary Acidic Protein
  • Guanidines
  • Lipopolysaccharides
  • Neurotoxins
  • Reactive Oxygen Species
  • Nitric Oxide
  • Oxidopamine
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Caspase 3
  • pimagedine